Former Chief Executive Officer · GYRE THERAPEUTICS, INC. (GYRE)

Charles Wu

A named executive officer of GYRE THERAPEUTICS in every fiscal year CompBrief holds from FY2022 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$15,350

Salary $12,500Stock awards $0

FY2023: $106,152

4th of 4 named executive officers at Gyre Therapeutics by FY2024 total.

4 named officers on file for GYRE THERAPEUTICS, FY2024

Charles Wu’s pay file — $29

  • 3 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how GYRE THERAPEUTICS’s whole pay program stands against its peers

  • GYRE THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on GYRE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 21, 2025 (DEF 14A).

Free

Get Charles Wu’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Charles Wu compensation by year

GYRE THERAPEUTICS Summary Compensation Table · all 3 fiscal years held
In US dollars, as GYRE THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024
Salary$78,347$106,152$12,500
Bonus$0$0$0
Stock awards$0$0$0
Option awards$0$0$0
Non-equity incentive$0$0$0
Pension and deferred compensation$0$0$0
All other$0$0$2,850
Total$78,347$106,152$15,350

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: GYRE THERAPEUTICS, INC. DEF 14A filed April 21, 2025, accession 0001140361-25-014779, and prior-year filings. Open the filing on EDGAR.

How this page was built: the GYRE THERAPEUTICS, INC. filed document, accession 0001140361-25-014779. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2025.

$78K
$106K
$15K
FY22
FY23
FY24
SalaryAll other

GYRE THERAPEUTICS’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Han YingChief Executive Officer$2,888,140
Ruoyu ChenChief Financial Officer$650,516
Weiguo YeChief Operating Officer$332,619
Charles Wu · this pageFormer Chief Executive Officer$15,350

Board service

GYRE THERAPEUTICS board · FY2023

How this board is paid

Company policy: GYRE THERAPEUTICS pays directors a $40,000 cash retainer. As stated in GYRE THERAPEUTICS's FY2023 proxy.

The full GYRE THERAPEUTICS compensation record

free company brief

This page is one person within GYRE THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are GYRE THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Charles Wu's compensation dossier · One-time report. No refunds.